MedMira (TSXV:MIR) Debt-to-Asset : 2.00 (As of Jan. 2024)

View and export this data going back to 1999. Start your Free Trial

What is MedMira Debt-to-Asset?

MedMira's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$6.28 Mil. MedMira's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$2.64 Mil. MedMira's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jan. 2024 was C$4.47 Mil. MedMira's debt to asset for the quarter that ended in Jan. 2024 was 2.00.

MedMira Debt-to-Asset Historical Data

The historical data trend for MedMira's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Debt-to-Asset Chart

MedMira Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Debt-to-Asset

Get a 7-Day Free Trial

34.03

3.51

2.97

2.17

2.54

MedMira Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Asset	Get a 7-Day Free Trial															2.39	2.44	2.54	2.02	2.00

Competitive Comparison of MedMira's Debt-to-Asset

For the Biotechnology subindustry, MedMira's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedMira's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where MedMira's Debt-to-Asset falls into.

MedMira Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

MedMira's Debt-to-Asset for the fiscal year that ended in Jul. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(6.314	+	2.957)	/	3.652
	=	2.54

MedMira's Debt-to-Asset for the quarter that ended in Jan. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(6.284	+	2.643)	/	4.465
	=	2.00

MedMira (TSXV:MIR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

MedMira Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of MedMira's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

MedMira (TSXV:MIR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (TSXV:MIR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

MMIRF:USA 47M:Germany

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.